Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase 3 trial of bevacizumab▼ (bev)-containing therapy ∓atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)
IMagyn050 is a phase 3 study investigating the efficacy and safety of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab▼ to patients with newly-diagnosed stage III or stage IV ovarian cancer. In the current presentation, the co-primary endpoints of the study (PFS and OS in the ITT and PD-L1+ populations) are presented.